Patent ductus arteriosus and indomethacin treatment as independent risk factors for plus disease in retinopathy of prematurity

Irena Tsui, Edward Ebani, Jamie B. Rosenberg, Juan Lin, Robert M. Angert, Umar K. Mian

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: To examine whether clinically significant patent ductus arteriosus (PDA) or indomethacin treatment are associated with plus disease or retinopathy of prematurity (ROP) requiring treatment. Methods: Retrospective, cross-sectional study. Charts were reviewed for gestational age, birth weight, birth head circumference, birth length, maternal characteristics, gender, bronchopulmonary dysplasia, neurologic comorbidities, PDA and its treatments, gastrointestinal comorbidities, blood transfusions, and sepsis. Main outcome measures were increased rates of plus disease or ROP requiring treatment. Results: A total of 450 premature infants screened for ROP in a mid-sized, urban neonatal intensive care unit were included. On univariate analysis, gestational age, birth weight, birth head circumference, birth length, bronchopulmonary dysplasia, neurologic comorbidities, PDA and its treatments, gastrointestinal comorbidities, and sepsis were significantly correlated to plus disease and ROP requiring treatment. PDA was significantly associated with bronchopulmonary dysplasia, neurologic comorbidities, sepsis, and blood transfusions (P < .0001). With type 3 multivariate analysis, only gestational age and bronchopulmonary dysplasia were independent risk factors for ROP. Conclusion: PDA and indomethacin were associated with plus disease and ROP requiring treatment on univariate analysis but this was not significant after adjusting for other risk factors. PDA was also strongly related to bronchopulmonary dysplasia and blood transfusions, which may explain its eff ect on ROP.

Original languageEnglish (US)
Pages (from-to)88-92
Number of pages5
JournalJournal of Pediatric Ophthalmology and Strabismus
Volume50
Issue number2
DOIs
StatePublished - Mar 2013

Fingerprint

Retinopathy of Prematurity
Patent Ductus Arteriosus
Indomethacin
Bronchopulmonary Dysplasia
Comorbidity
Parturition
Blood Transfusion
Nervous System
Gestational Age
Sepsis
Birth Weight
Therapeutics
Head
Neonatal Intensive Care Units
Premature Infants
Multivariate Analysis
Cross-Sectional Studies
Mothers
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology
  • Pediatrics, Perinatology, and Child Health

Cite this

@article{69f50cb5ac054c3eb0ae7bf8a0dd6a03,
title = "Patent ductus arteriosus and indomethacin treatment as independent risk factors for plus disease in retinopathy of prematurity",
abstract = "Purpose: To examine whether clinically significant patent ductus arteriosus (PDA) or indomethacin treatment are associated with plus disease or retinopathy of prematurity (ROP) requiring treatment. Methods: Retrospective, cross-sectional study. Charts were reviewed for gestational age, birth weight, birth head circumference, birth length, maternal characteristics, gender, bronchopulmonary dysplasia, neurologic comorbidities, PDA and its treatments, gastrointestinal comorbidities, blood transfusions, and sepsis. Main outcome measures were increased rates of plus disease or ROP requiring treatment. Results: A total of 450 premature infants screened for ROP in a mid-sized, urban neonatal intensive care unit were included. On univariate analysis, gestational age, birth weight, birth head circumference, birth length, bronchopulmonary dysplasia, neurologic comorbidities, PDA and its treatments, gastrointestinal comorbidities, and sepsis were significantly correlated to plus disease and ROP requiring treatment. PDA was significantly associated with bronchopulmonary dysplasia, neurologic comorbidities, sepsis, and blood transfusions (P < .0001). With type 3 multivariate analysis, only gestational age and bronchopulmonary dysplasia were independent risk factors for ROP. Conclusion: PDA and indomethacin were associated with plus disease and ROP requiring treatment on univariate analysis but this was not significant after adjusting for other risk factors. PDA was also strongly related to bronchopulmonary dysplasia and blood transfusions, which may explain its eff ect on ROP.",
author = "Irena Tsui and Edward Ebani and Rosenberg, {Jamie B.} and Juan Lin and Angert, {Robert M.} and Mian, {Umar K.}",
year = "2013",
month = "3",
doi = "10.3928/01913913-20130108-03",
language = "English (US)",
volume = "50",
pages = "88--92",
journal = "Journal of Pediatric Ophthalmology and Strabismus",
issn = "0191-3913",
publisher = "Slack Incorporated",
number = "2",

}

TY - JOUR

T1 - Patent ductus arteriosus and indomethacin treatment as independent risk factors for plus disease in retinopathy of prematurity

AU - Tsui, Irena

AU - Ebani, Edward

AU - Rosenberg, Jamie B.

AU - Lin, Juan

AU - Angert, Robert M.

AU - Mian, Umar K.

PY - 2013/3

Y1 - 2013/3

N2 - Purpose: To examine whether clinically significant patent ductus arteriosus (PDA) or indomethacin treatment are associated with plus disease or retinopathy of prematurity (ROP) requiring treatment. Methods: Retrospective, cross-sectional study. Charts were reviewed for gestational age, birth weight, birth head circumference, birth length, maternal characteristics, gender, bronchopulmonary dysplasia, neurologic comorbidities, PDA and its treatments, gastrointestinal comorbidities, blood transfusions, and sepsis. Main outcome measures were increased rates of plus disease or ROP requiring treatment. Results: A total of 450 premature infants screened for ROP in a mid-sized, urban neonatal intensive care unit were included. On univariate analysis, gestational age, birth weight, birth head circumference, birth length, bronchopulmonary dysplasia, neurologic comorbidities, PDA and its treatments, gastrointestinal comorbidities, and sepsis were significantly correlated to plus disease and ROP requiring treatment. PDA was significantly associated with bronchopulmonary dysplasia, neurologic comorbidities, sepsis, and blood transfusions (P < .0001). With type 3 multivariate analysis, only gestational age and bronchopulmonary dysplasia were independent risk factors for ROP. Conclusion: PDA and indomethacin were associated with plus disease and ROP requiring treatment on univariate analysis but this was not significant after adjusting for other risk factors. PDA was also strongly related to bronchopulmonary dysplasia and blood transfusions, which may explain its eff ect on ROP.

AB - Purpose: To examine whether clinically significant patent ductus arteriosus (PDA) or indomethacin treatment are associated with plus disease or retinopathy of prematurity (ROP) requiring treatment. Methods: Retrospective, cross-sectional study. Charts were reviewed for gestational age, birth weight, birth head circumference, birth length, maternal characteristics, gender, bronchopulmonary dysplasia, neurologic comorbidities, PDA and its treatments, gastrointestinal comorbidities, blood transfusions, and sepsis. Main outcome measures were increased rates of plus disease or ROP requiring treatment. Results: A total of 450 premature infants screened for ROP in a mid-sized, urban neonatal intensive care unit were included. On univariate analysis, gestational age, birth weight, birth head circumference, birth length, bronchopulmonary dysplasia, neurologic comorbidities, PDA and its treatments, gastrointestinal comorbidities, and sepsis were significantly correlated to plus disease and ROP requiring treatment. PDA was significantly associated with bronchopulmonary dysplasia, neurologic comorbidities, sepsis, and blood transfusions (P < .0001). With type 3 multivariate analysis, only gestational age and bronchopulmonary dysplasia were independent risk factors for ROP. Conclusion: PDA and indomethacin were associated with plus disease and ROP requiring treatment on univariate analysis but this was not significant after adjusting for other risk factors. PDA was also strongly related to bronchopulmonary dysplasia and blood transfusions, which may explain its eff ect on ROP.

UR - http://www.scopus.com/inward/record.url?scp=84877641933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877641933&partnerID=8YFLogxK

U2 - 10.3928/01913913-20130108-03

DO - 10.3928/01913913-20130108-03

M3 - Article

VL - 50

SP - 88

EP - 92

JO - Journal of Pediatric Ophthalmology and Strabismus

JF - Journal of Pediatric Ophthalmology and Strabismus

SN - 0191-3913

IS - 2

ER -